GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Rifaximin tablets (adults)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Xifaxan

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Rifaximin tablets (adults) - selected U.S. labeling

Product / population
Adult oral rifaximin tablets for the labeled traveler-diarrhea, hepatic-encephalopathy-recurrence and IBS-D uses. Not rifampin or rifabutin.
Renal measure
No renal pharmacokinetic study or numeric adjustment algorithm in the selected label.
Labeled basic dosing
IndicationAdult oral schedule
Noninvasive E. coli travelers' diarrhea200 mg three times daily for 3 days
Reduce overt hepatic encephalopathy recurrence550 mg twice daily
IBS with diarrhea550 mg three times daily for 14 days; up to two repeat courses for recurrence

Renal information and dialysis

The label states that renal-impairment pharmacokinetics have not been studied. It does not establish a numeric renal or dialysis regimen. Do not reclassify this as a label-proven no-adjustment statement.

Selected warnings and limits

Do not use the traveler-diarrhea regimen for fever, bloody stool or suspected invasive pathogens. Severe hepatic disease increases exposure; review P-glycoprotein inhibitors.

Source revision: Label revision date not separately recorded; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5e8e2fd-7087-4b78-9181-cc259c0be2f1

Scope: Selected dosing/renal sections read; concise local summary, not full prescribing information. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Rifaximin tablets (adults) - selected U.S. labeling

Adult oral rifaximin tablets for the labeled traveler-diarrhea, hepatic-encephalopathy-recurrence and IBS-D uses. Not rifampin or rifabutin.

Renal method: No renal pharmacokinetic study or numeric adjustment algorithm in the selected label.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - XIFAXAN

Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.

Adult oral rifaximin; selected renal evidence limitation, not a complete indication-specific course.

Renal method: Renal pharmacokinetics not studied in the selected label section.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
Handbook

Renal Drug Handbook, fifth edition - Rifaximin tablets (adults)

Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.

Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Retrieved: 2026-09-05

Read local renal result

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source

Rifaximin tablets (adults) - selected U.S. labeling

Adult oral rifaximin tablets for the labeled traveler-diarrhea, hepatic-encephalopathy-recurrence and IBS-D uses. Not rifampin or rifabutin.

Method: No renal pharmacokinetic study or numeric adjustment algorithm in the selected label.

Renal information and dialysisRead this complete source summary
Handbook source

Renal Drug Handbook, fifth edition - Rifaximin tablets (adults)

Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.

Method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.

Historical renal and dialysis observationsRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeRifaximin tablets (adults) - selected U.S. labelingGlobalRPh RX List - XIFAXANRenal Drug Handbook, fifth edition - Rifaximin tablets (adults)
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5e8e2fd-7087-4b78-9181-cc259c0be2f1

Product and population scope

Adult oral rifaximin tablets for the labeled traveler-diarrhea, hepatic-encephalopathy-recurrence and IBS-D uses. Not rifampin or rifabutin.

RDM31-rifaximin-scope · Source section: Editorial scope tied to selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Rifaximin tablets (adults) - selected U.S. labeling

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adult oral rifaximin tablets for the labeled traveler-diarrhea, hepatic-encephalopathy-recurrence and IBS-D uses. Not rifampin or rifabutin.

Renal method: No renal pharmacokinetic study or numeric adjustment algorithm in the selected label.
Source date: Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved: 2026-09-05

Selected dosing/renal sections read; concise local summary, not full prescribing information.

Labeled basic dosing

IndicationAdult oral schedule
Noninvasive E. coli travelers' diarrhea200 mg three times daily for 3 days
Reduce overt hepatic encephalopathy recurrence550 mg twice daily
IBS with diarrhea550 mg three times daily for 14 days; up to two repeat courses for recurrence

RDM31-rifaximin-label-dose · Source locator: 2.1-2.3

Renal information and dialysis

The label states that renal-impairment pharmacokinetics have not been studied. It does not establish a numeric renal or dialysis regimen. Do not reclassify this as a label-proven no-adjustment statement.

RDM31-rifaximin-label-renal · Source locator: 8.6; 12.3

Selected warnings and limits

Do not use the traveler-diarrhea regimen for fever, bloody stool or suspected invasive pathogens. Severe hepatic disease increases exposure; review P-glycoprotein inhibitors.

RDM31-rifaximin-label-limits · Source locator: 1.1; 5.1, 5.4, 5.5

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5e8e2fd-7087-4b78-9181-cc259c0be2f1
Retrieved
2026-09-05
DailyMed Set ID
c5e8e2fd-7087-4b78-9181-cc259c0be2f1
Renal-function method
No renal pharmacokinetic study or numeric adjustment algorithm in the selected label.
Source date/version
Label revision date not separately recorded; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or label PDF.
Local summary SHA-256
1fca4a973c5655da1ae8321b4929083bacb61a03b0cda5110b66bf0590a1f1ee
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - XIFAXAN

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult oral rifaximin; selected renal evidence limitation, not a complete indication-specific course.

Renal method: Renal pharmacokinetics not studied in the selected label section.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Rifaximin pharmacokinetics have not been studied in patients with impaired renal function. The nearby no-adjustment statement in this source concerns hepatic impairment and local intestinal activity; it is not a directly studied renal or dialysis regimen. Match the intended indication and formulation before using an institutional recommendation.

RDM35-rxlist-rifaximin-617fd99576-C1 · Source locator: Renal impairment; dosage; warnings; pharmacokinetics, as identified in the selected retrieval.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/xifaxan-drug/
Retrieved
2026-09-07
Renal-function method
Renal pharmacokinetics not studied in the selected label section.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
43991349e5a49069bb578fd2d64528e591c0b1679b6835b98c9d04b3ab3d1f65
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, fifth edition - Rifaximin tablets (adults)

Open / share this exact local source

UK Renal Pharmacy Group / CRC Press · Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.

Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Source date: Fifth edition, 2019
Retrieved: 2026-09-05

Historical source, separately displayed. Renal tables were read with page-image inspection.

Historical renal and dialysis observations

The historical table retains usual dosing at 20-50, 10-20 and below 10 mL/min. Removal is considered unlikely in peritoneal, HD, high-flux/HDF and continuous modalities. It separately cautions about the higher encephalopathy dose in renal impairment.

RDM31-rifaximin-book · Source locator: Dose in renal impairment; renal replacement therapies; Other information

Source-specific limits

The book offers practice advice despite the label's missing renal pharmacokinetic study. This is not two-source proof of dialysis dosing.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page(s) 881; PDF page(s) 900
Renal-function method
Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Source date/version
Fifth edition, 2019
U.S. product identity basis
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5e8e2fd-7087-4b78-9181-cc259c0be2f1
Hash meaning
SHA-256 identifies the local paraphrase; the source PDF is not redistributed.
Local summary SHA-256
e71f51a028d344da977e52d9a525a222acb21bbf81258177d5e59ccc9cd2ed2e

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5e8e2fd-7087-4b78-9181-cc259c0be2f1
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
afeab1d14e0a22828462464af597a7d8d96a155429295495c2adfecee8e3c741
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report